Good Girl LLC dba GoodGirlRX
FDA issued a warning letter to Good Girl LLC dba GoodGirlRX (CEO Savannah Chrisley) in February 2026 after reviewing the company's website in December 2025 and finding false or misleading claims about compounded semaglutide and tirzepatide products. The website falsely labeled products as if GoodGirlRX were the compounder, and made claims that compounded drugs were 'FDA-approved' or 'clinically proven,' when compounded drugs are not FDA-approved. FDA found the products misbranded under FDCA sections 502(a) and 502(bb), and warned that failure to address violations may result in seizure or injunction.
Flagged claims (4)
FDA-approved meds.
Clinically proven GLP-1 results
GoodGirlRX
FDA-approved options
Required actions (3)
Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.
Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].
Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.
Run my free site audit